A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Nammi Therapeutics Inc
Revolution Medicines, Inc.
Conjupro Biotherapeutics, Inc.
Whitehawk Therapeutics, Inc.
National Cancer Institute (NCI)
SystImmune Inc.
M.D. Anderson Cancer Center
Institut Paoli-Calmettes
Eli Lilly and Company
ViroMissile, Inc.
Tizona Therapeutics, Inc
National Institutes of Health Clinical Center (CC)
Clasp Therapeutics, Inc.
Royal Marsden NHS Foundation Trust
SystImmune Inc.
Pheon Therapeutics
Eli Lilly and Company
Seagen Inc.
Novartis
Seagen Inc.
Degron Therapeutics Co.
University Health Network, Toronto
Chongqing Precision Biotech Co., Ltd
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Novartis
Sichuan Enray Pharmaceutical Sciences Company
Novita Pharmaceuticals, Inc.
Anhui Provincial Hospital
Lyell Immunopharma, Inc.
M.D. Anderson Cancer Center
Compugen Ltd
Monopar Therapeutics
Monopar Therapeutics
Black Diamond Therapeutics, Inc.
Revolution Medicines, Inc.
Tomsk National Research Medical Center of the Russian Academy of Sciences
Rutgers, The State University of New Jersey
Inspirna, Inc.
Checkpoint Therapeutics, Inc.
Compugen Ltd
Vincerx Pharma, Inc.
Tesaro, Inc.
Pfizer
Celldex Therapeutics
STCube, Inc.
Lebanese University